Peptide nucleic acids (PNAs) represent a revolutionary class of synthetic nucleic acid analogues, in which the traditional sugar–phosphate backbone is replaced by a neutral N-(2-aminoethyl) glycine ...

So far, 2013 has been a good year for antisense technology. In fact, it’s been great. In January the FDA OK’d Isis Pharmaceuticals’ Kynamro™ (mipomersen sodium), the only currently marketed antisense ...

Cure Rare Disease has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for ...

Peptides and oligonucleotides, often grouped together as TIDES, are increasingly seen as powerful therapeutic tools. 2 Their high specificity, tunable biological activity, and ability to modulate ...